Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Articles in this issue

---

ASH 2020: Clinical Updates

ASH 2020: COVID-19 and Hematology

ASH 2020: CAR T-Cell Therapy Updates

ASH 2020: The Next Wave

2020 SABCS: Topics in Precision Oncology

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

October 1st 2024

ACS 2024 Report Shows Breast Cancer Equity Gap

Cameron Santoro

The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

September 17th 2024

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

Cameron Santoro

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

September 10th 2024

Breast Density Disclosure Now Mandated for Mammograms

Cameron Santoro

Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.

September 5th 2024

AI-Enhanced Breast Cancer Screening Economically Viable in the UK

Cameron Santoro

Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.

Related Content

Advertisement

October 1st 2024

ACS 2024 Report Shows Breast Cancer Equity Gap

Cameron Santoro

The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

September 17th 2024

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

Cameron Santoro

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

September 10th 2024

Breast Density Disclosure Now Mandated for Mammograms

Cameron Santoro

Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.

September 5th 2024

AI-Enhanced Breast Cancer Screening Economically Viable in the UK

Cameron Santoro

Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.